Lilly Asia Ventures was among the participants in a series C round closed by the Ant Group and China Re-backed healthcare payment platform operator.

China-based healthcare payment platform MediTrust Health completed a series C round today sized at over RMB2bn ($308m) featuring Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly.

Private equity group Boyu Capital and investment firm Janchor Partners co-led the round, which included B Capital Group, a venture capital offshoot of professional services firm Boston Consulting Group, as well as Bank of China Group Investment, on behalf of financial services firm Bank of China.

The round was filled…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn